Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to
evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).